Table 1.

Immunohistochemical staining of EML4-ALK–positive or EML4-ALK–negative NSCLC specimens and quantitation of ALK mRNA

Tumor IDEML4-ALK variantStaining intensity
ALK mRNA level
ALK1ALK1 with iAEP5A45A4 with iAEPSP8SP8 with iAEP5′ region3′ region
#4808V1+++1.357.3
#9034V1+++++−/+++083.3
#9968V1+++15.9150.1
#2374V2++−/+++−/+++1182.3
#3121V2++−/+++−/+++0118.6
#4180V2++−/+++−/+++1.4124.5
#2075V3++−/+++−/+++772
#7969V3++++++++++++3.652.7
#9616V3−/+++++++++5.733.8
#8398V4++−/+++−/+++0118.6
#8993V5++−/+++−/+++1.161.4
NC #1NA−/+11
NC #2NA−/+1.25.5
NC #3NA−/++0.98.8
NC #4NA−/+−/+++4.11.4
NC #5NA+0.62.2
NC #6NA+0.31.1
NC #7NA−/++4.82.7
NC #8NA+1.73.8
NC #9NA+1.53.3
NC #10NA−/+−/+++2.53
  • NOTE: Tumor specimens of the test cohort were subjected to immunohistochemical staining with the antibody preparations ALK1, 5A4, or SP8 according to the standard protocol or by the iAEP method. Staining intensity is represented as follows: +++, strongly positive; ++, positive; +, weakly but definitely positive; −/+, indeterminate; −, negative. The abundance of ALK mRNA in the specimens was determined by real-time RT-PCR analysis with the primers targeted to the 5′ or 3′ regions, which correspond to the extracellular and intracellular portions, respectively, of ALK; data are normalized relative to the NC (negative control) #1 specimen.

    Abbreviation: NA, not applicable.